Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a
smoldering inflammatory activity is present from the earliest stages of the disease and …

The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter
lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective …

Importance Biomarkers distinguishing nonrelapsing progressive disease biology from
relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an …

Objective Analysis of postmortem multiple sclerosis (MS) tissues combined with in vivo
disease milestones suggests that whereas perivascular white matter infiltrates are …

Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

Multiple sclerosis is an inflammatory and degenerative disease characterized by different
clinical courses including relapsing multiple sclerosis (RMS) and primary progressive …

Drug delivery systems (DDS) have recently emerged as a promising approach for the
unique advantages of drug protection and targeted delivery. However, the access of …

Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …

Background People living with multiple sclerosis (MS) face a higher likelihood of being
diagnosed with a depressive disorder than the general population. Although many low-cost …